Singulomics, established in New York in 2016, is a privately-held biotechnology company that aims to transform single-cell omics research and unlock its many applications in biology and medicine. Building on the unmatched expertise in single-cell genomics, transcriptomics and epigenomics developed since the mid-2000s at Albert Einstein College of Medicine, we develop and provide high-quality, innovative single-cell services to academic and industrial communities around the world.